QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Tarlatamab, DLL3×CD3 T-Cell Engagement, ES-SCLC and Product Pharmacovigilance

Test your understanding of the concepts covered by Tarlatamab: DLL3×CD3 T-Cell Engagement, Small-Cell Lung Cancer and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which clinical context is especially important when distinguishing hypoxia from CRS in a patient with ES-SCLC?

The possibility of pneumonia, pulmonary embolism, baseline lung disease or tumour-related respiratory compromise The patient's preferred chemotherapy regimen from a previous line The absence of a CD3-positive lymphocyte count in the case report The fact that all hypoxia after infusion is necessarily allergic

Question 2 of 10 A patient develops confusion and word-finding difficulty 30 hours after discharge following Cycle 1 Day 8. What is the most appropriate immediate pharmacovigilance interpretation?

The event cannot be related to treatment because it began after discharge The event is automatically ICANS because the patient received a T-cell engager The event warrants urgent neurologic evaluation and assessment for ICANS and alternative causes The event should be recorded only as cancer-related fatigue

Question 3 of 10 Which statement best reflects the relationship between tarlatamab's efficacy and its safety risks?

Efficacy depends on blocking all T-cell activity, whereas toxicity results from unrelated off-target binding Both efficacy and CRS-related toxicity arise from strong T-cell engagement, so risk management aims to control intensity and timing rather than eliminate immune activation Efficacy occurs only through direct poisoning of tumour cells, while CRS is caused by the formulation vehicle Safety risks disappear when DLL3 is present because target binding prevents systemic cytokine release

Question 4 of 10 Which data element best supports biological traceability for a tarlatamab case?

The patient's smoking history alone The product name and batch or lot number where available The date of the patient's original cancer diagnosis only The brand of intravenous fluid used

Question 5 of 10 Why is monitoring more intensive after the earliest tarlatamab doses than after later tolerated doses?

Tarlatamab accumulates permanently after every dose, so later doses are intrinsically more toxic The strongest acute cytokine responses and most frequent CRS events occur during initial T-cell engagement Patients lose all risk of infection after the first treatment cycle Later doses do not activate T cells and therefore require monitoring only for infusion-site reactions

Question 6 of 10 Why should an aggregate CRS analysis stratify cases by cycle and dose rather than pooling all events together?

Because CRS is expected to occur only after the fifth cycle Because pooling can obscure the expected early-dose concentration and conceal unusual late clusters Because cycle information is needed to calculate tumour DLL3 expression Because later doses use a different active substance

Question 7 of 10 A patient with severe CRS has hypotension requiring vasopressors, hypoxia requiring respiratory support and hepatic dysfunction. Which approach best supports severity assessment?

Use the patient's general description that the event was 'very severe' without objective data Assess objective cardiovascular, respiratory and organ-function findings, together with required interventions Base severity only on whether the patient received tocilizumab Grade the event according to tumour response rather than physiologic impairment

Question 8 of 10 Which additional information is most important when evaluating a tarlatamab administration error?

Whether the error reached the patient and what clinical consequence followed Only the name of the dispensing pharmacy Only whether the patient had previously responded to chemotherapy The patient's preference for inpatient or outpatient care

Question 9 of 10 Which observation is most useful when interpreting a liver-test abnormality during tarlatamab treatment?

Whether the patient received any prior platinum-based therapy, without considering timing Whether the liver-test increase occurred during or after CRS and associated hypotension Whether the patient had a caregiver during the infusion Whether the tumour expressed CD3

Question 10 of 10 A pharmacy prepares a 10 mg vial for Cycle 1 Day 1, but the error is identified before administration and the patient receives no drug. How should this event primarily be characterised?

A confirmed Grade 2 CRS case An adverse reaction caused by excessive first exposure A near-miss medication error without an adverse reaction A product-quality defect caused by DLL3 variability

Knowledge Assessment: Tarlatamab, DLL3×CD3 T-Cell Engagement, ES-SCLC and Product Pharmacovigilance

Cookie Settings